PharmaCyte Biotech (PMCB) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $1.6 million), about 2.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMCB | SCNI |
|---|---|---|
| Share price | $0.3975 | $1.19 |
| Market cap | $4.27M | $1.61M |
| 1-day change | -1.58% | -1.65% |
| P/E ratio (TTM) | — | 0.04 |
| EPS (TTM) | $-2.31 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.51 | $15.65 |
| 52-week low | $0.3339 | $1.06 |
| Distance from 52-week high | -73.68% | -92.40% |
| Average volume | 205.72K | 1.10M |
| Shares outstanding | 10.74M | 1.35M |
| Employees | 2 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PharmaCyte Biotech is about 2.7 times larger than Scinai Immunotherapeutics by market value ($4.27M vs $1.61M).
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
PMCB vs SCNI FAQ
Which is bigger, PharmaCyte Biotech or Scinai Immunotherapeutics?
PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $1.61M for Scinai Immunotherapeutics (SCNI).
Are PharmaCyte Biotech and Scinai Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.